Ophthalmology Times

FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Healio

FDA fast tracks CTx001 for geographic atrophy

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Nature

C5a Receptors and Their Role in Innate Immunity

The complement component C5a and its receptors, C5aR1 and C5aR2, are central to the orchestration of innate immunity. C5a is a potent anaphylatoxin generated during complement activation, acting as a ...